MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Ketamir-2 Results; DEA Confirms Not Controlled Substance
MIRA is trading near its 52-week low of $0.9 (8.3% above the low).
Summary
MIRA Pharmaceuticals announced positive unblinded Phase 1 results for Ketamir-2, showing strong safety and a favorable pharmacokinetic profile, alongside a crucial DEA ruling that the drug is not a controlled substance.
Key Events · Product Development and Regulatory · MIRA
-
Positive Unblinded Phase 1 Results
Ketamir-2 showed strong safety and tolerability in 57 healthy volunteers, with fewer adverse events reported in the treatment group compared to placebo.
-
Favorable Pharmacokinetics
The drug demonstrated rapid oral absorption, dose-proportional exposure, and a half-life supporting potential once-daily administration.
-
DEA Not a Controlled Substance
The U.S. Drug Enforcement Administration determined that Ketamir-2 is not classified as a controlled substance, significantly de-risking its regulatory and commercial path.
-
Advancing to Phase 2a
The company is preparing for Phase 2a clinical protocol submission to the FDA for evaluation in chemotherapy-induced peripheral neuropathy (CIPN).
Analysis · MIRA · Life Sciences
This filing provides critical positive unblinded Phase 1 clinical trial results for Ketamir-2, demonstrating a strong safety profile with fewer adverse events than placebo, and a pharmacokinetic profile supporting once-daily dosing. The most significant update is the U.S. DEA's determination that Ketamir-2 is not classified as a controlled substance, which substantially de-risks the drug's commercial pathway and broadens its market potential. This positive development is particularly important for a company that recently issued a going concern warning.
At the time of this filing, MIRA was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.8M. The 52-week trading range was $0.90 to $2.45. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.